Victoza for weight loss: what the liraglutide hype gets wrong

What did @espaciomedicoestetico actually say?

Honestly, this is a hard video to fact-check because the transcript is largely incoherent. The creator appears to be responding to audience questions about Victoza, a brand-name liraglutide injection made by Novo Nordisk, and the video is tagged with Kim Kardashian's name alongside medical hashtags. But the actual spoken content captured in the transcript reads as garbled repetition with no discernible medical claims extracted. What we can work with is the context: a medical aesthetics account in Mexico, 433,000 views, and an audience clearly hungry for information about GLP-1 drugs being talked about in celebrity circles.

The framing itself, connecting Victoza to beauty culture and celebrity, is worth examining on its own. Victoza is a prescription medication approved for type 2 diabetes management and, separately, for chronic weight management in adults under the brand Saxenda. Treating it as a beauty trend is a choice with real clinical implications.

Does the science back up the Victoza-for-weight-loss framing?

Yes and no, and the distinction matters a lot. Liraglutide does produce meaningful weight loss in clinical trials, but the effect sizes are more modest than the celebrity hype suggests, and the drug carries risks that get lost in TikTok aesthetics content.

The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) showed that 56% of participants on 3.0 mg liraglutide lost at least 5% of body weight over 56 weeks, compared to 23% on placebo. That is a real effect. But the mean weight loss was about 8 kg, not the dramatic transformations being implied in celebrity-adjacent content. More recent GLP-1 agents like semaglutide and tirzepatide outperform liraglutide on efficacy. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide producing up to 22.5% body weight reduction, making liraglutide look considerably less impressive by comparison. Presenting Victoza as a cutting-edge weight loss solution in 2024 is already a bit outdated.

What did they get wrong, or right?

Without extractable claims from the transcript, we have to assess the framing rather than specific statements. The celebrity-beauty angle is a problem. Liraglutide requires a valid prescription, proper screening for contraindications including a personal or family history of medullary thyroid carcinoma and MEN2 syndrome, and ongoing monitoring. Packaging it alongside hashtags for beauty and Kim Kardashian strips that context away entirely.

What the creator may be doing right is trying to bring accurate drug information to a Spanish-speaking audience that is already hearing about these drugs through celebrity gossip. That is not nothing. Health misinformation in Spanish-language content is a documented problem, and a licensed medical professional attempting to explain prescription medications to curious followers has genuine value, if the information is accurate and appropriately caveated. The problem is we cannot verify what was actually said in sufficient detail to give credit or assign blame for specific claims.

The Victoza-Kim Kardashian connection is also questionable on its face. Kardashian has been publicly associated with semaglutide rumors, not liraglutide specifically. The conflation of different GLP-1 drugs in celebrity discourse is itself a source of patient confusion.

What should you actually know about Victoza?

Victoza contains liraglutide at doses up to 1.8 mg daily and is FDA-approved for type 2 diabetes. Saxenda, the same molecule at 3.0 mg, is approved for chronic weight management in adults with a BMI of 30 or higher, or 27 with at least one weight-related comorbidity. These are not interchangeable approvals, and the dosing distinction matters clinically.

Side effects are real and common. Nausea affects roughly 40% of users in early weeks. Pancreatitis, gallbladder disease, and heart rate increases have been documented in post-marketing surveillance. The FDA requires a black box warning about thyroid C-cell tumors based on rodent studies, though human risk has not been established. Anyone seeing GLP-1 content on TikTok and considering self-prescribing or using compounded versions needs to understand these risks exist and require a clinician's evaluation, not a social media recommendation.

• Liraglutide is not the most effective GLP-1 available as of 2024.
• Weight regain after stopping liraglutide is well-documented and significant.
• Compounded liraglutide is not equivalent to brand-name Victoza or Saxenda and carries additional quality and dosing uncertainty.

The bottom line on this video

A 433,000-view video about a prescription GLP-1 drug, tagged with a celebrity's name and beauty hashtags, deserves scrutiny regardless of what the creator actually said. The context alone creates an environment where viewers may come away thinking Victoza is a beauty treatment rather than a regulated medication with specific indications and real risks. If this creator is a licensed physician, as the hashtag suggests, the responsibility to contextualize appropriately is higher, not lower. Good intentions and reach do not cancel out the risk of inadequate informed consent at scale.